Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 733-734

  Libby, Edward ^a   Candelaria Quintana, Dulcinea ^a   Moualla, Hayan ^a   Abdul Jaleel, Maryam ^a   Rabinowitz, Ian ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; MELPHALAN; PREDNISOLONE; PYRAZINE DERIVATIVE;

CASE REPORT; FEMALE; HUMAN; LEUKEMIA, PLASMA CELL; REMISSION; VERY ELDERLY;

AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; LEUKEMIA, PLASMA CELL; MELPHALAN; PREDNISOLONE; PYRAZINES; REMISSION INDUCTION;

EID: 77956487480     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21790     Document Type: Letter

References (20)

1. Jimenez-Zepeda VH, Dominguez-Martinez VJ. Plasma cell leukemia: A highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol 2009;89:259-268.
2. Gertz MA. Managing plasma cell leukemia. Leuk lymphoma 2007;48:5-6.
3. San Miguel JF, Schlag R, KhuagevaNK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
4. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: A Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 2009;115:5734-5739.
5. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22:1044-1052.
6. Chang H, Qi X, Yeung J, et al. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009;33:259-262.
7. Wohrer S, Ackermann J, Baldia C, et al. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - A case report. Hematol J 2004;5:361-363. (Pubitemid 39214215)
8. Benson DM Jr, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk lymphoma 2007;48:1423-1425. (Pubitemid 47079374)
9. Musto P, Pietrantuono G, Guariglia R, et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008;32:1637-1638.
10. Chan SM, George T, Cherry AM, Medeiros BC. Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: A case report. Cases J 2009;2:121.
11. Al-Nawakil C, Tamburini J, Bardet V, et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk lymphoma 2008;49:2012-2014.
12. Katodritou E, Verrou E, Gastari V, et al. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res 2008;32:1153-1156.
13. Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007;109:2285-2290.
14. Capalbo S, Chiefa A, Delia M, et al. Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement. Acta Oncol (Stockholm, Sweden). 2007;46:262-264. (Pubitemid 46272624)
15. Musto P, Barone M, Guariglia R, et al. Bortezomib and plasma cell leukemia: Blood. ASH Ann Meet Abstr 2006;108:Abstract 3546.
16. Pietrantuono G, Guariglia R, Villani O, et al. Bortezomib as front-line therapy in primary plasma cell leukemia: Blood. ASH Ann Meet Abstr 2008;112:Abstract 2784.
17. Caldera HJ, Fernandez GL, Leon B. Treatment of plasma cell leukemia (PCL) with Bortezomib and Thalidomide: A case report and literature review: Blood. ASH Ann Meet Abstr 2005;106:Abstract 5118.
18. Alegre A, AguadoB, Lahuerta JJ, et al. Clinical efficacy of Bortezomib based therapy in plasma cell Leukemias: Blood. ASH Annu Meet Abstr 2007;110:Abstract 2726.
19. Kaufman JL, Gleason C, Heffner L, Lonial S. Bortezomib, Thalidomide, and Dexamethasone as induction therapy for patients with symptomatic multiple Myeloma: Blood. ASH Ann Meet Abstr 2007;110:Abstract 3605.
20. Finnegan DP, Kettle P, Drake M, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006;47:1670-1673. (Pubitemid 44364036)